Searched for
ONESOURCE SPECIALTY PHARMA
Ahead of Market: 10 things that will decide stock market action on MondayMarkets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...- Market Trading Guide: Balrampur Chini, OneSource among 5 stocks for gains up to 11% on WednesdayNifty extended its losing streak amid heavy selling in IT, banking, auto, and consumer stocks as bearish sentiment intensified. Analysts id...
- Earnings season is strong, but Q1 pain is coming: Dipan MehtaMarket expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...
- What war? Smallcap stocks defy Middle East tensions with up to 56% gains in 2 months as Nifty slidesDespite Middle East tensions and a sliding Nifty50, India's smallcap stocks have surged up to 56% in two months. While institutional desks ...
- Concurrent Gainers: 12 stocks that gained for 5 straight sessionsDespite a falling Sensex, twelve BSE 500 stocks delivered consistent gains across five sessions, led by Onesource Specialty Pharma and Wels...
- Promoters Buying: 9 Nifty 500 stocks that saw stake hikes in March quarterPromoters are showing increased confidence in several Nifty 500 companies. Their shareholding has risen in the March 2026 quarter compared ...
- Positive Breakout: These 8 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
- Pharma stocks buck market weakness as Dr Reddy's gainsPharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...
- How Ashish Kacholia, Mukul Agrawal, Madhu Kela, Dolly Khanna reshuffled portfolios amid Iran war?Amid a sharp market sell-off triggered by Iran war tensions and rising oil prices, marquee investors like Ashish Kacholia, Mukul Agrawal, M...
- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic markets extended gains for a third session, led by financial and FMCG stocks, with Nifty 50 and BSE Sensex rising sharply. Lower v...
- OneSource Specialty Pharma shares nosedive 18% on weak Q3. Here’s what happenedOneSource Specialty Pharma shares plunged 18% after reporting a net loss of Rs 47 crore for the December quarter, a significant reversal fr...
- Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launchNovo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide ...
- JM Financial initiates coverage on OneSource Specialty Pharma with a Buy call, target price Rs 2,049JM Financial initiates a Buy call on OneSource Specialty Pharma, setting a target price of Rs 2,049, driven by its unique CDMO positioning ...
- 360 ONE Asset acquires stake in OneSource Specialty Pharma360 ONE Asset has acquired a stake in OneSource Specialty Pharma, a Contract Development and Manufacturing Organization (CDMO), for an undi...
- Strides Pharma's OneSource raises Rs 801 crore in pre-listing roundOneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and W...
- OneSource in talks to raise Rs 1,670 crore in pre-listing roundOneSource, a TPG Growth-backed specialty pharma CDMO, is in talks with investors to raise $200 million. The company, formerly Stelis Biopha...
- Strides secures shareholders' nod for OneSource specialty CDMO unitStrides Pharma Science has received approval from shareholders and secured creditors to create OneSource, a specialty pharma CDMO. The comp...
- Proxy advisors vote against Strides Pharma’s consolidation schemeProxy advisory firms have recommended investors vote against Strides Pharma's proposal to consolidate businesses with Steriscience and Ones...
- Strides Pharma shares fall over 3% on plans to spin off CDMO, gelatin businessesAs per Trendlyne data, the average target price of Strides Pharma is Rs 530, which shows a downside of 2% from the current market prices. T...
- Strides Pharma to spin off CDMO assets to form a separate unitPharmaceutical company Strides Pharma is planning to demerge its contract development and manufacturing services (CDMO) assets into an asso...
Load More
